ClinicalTrials.gg
CompletedNCT04265456Updated Aug 5, 2020

A Phase 1 Study to Evaluate Pregabalin and Acetaminophen in Healthy Volunteers

A Phase 1 interventional study of Pregabalin 100mg and Acetaminophen 1300mg in Postoperative Pain, sponsored by Nevakar, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-05.

Sponsored by Nevakar, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2020, 6 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies testing pregabalin in Pain, Postoperative — 7 open to participants now, 7 under way, 1 of them phase 3. Pregabalin · Pain, Postoperative.

Enrollment
49th of 65
63 · median 90
Started
2020
with 4 others
Phase 1
5 of 65
1 open now
Registered
46th of 65
by date
Lead sponsor
2 of 65
Nevakar, Inc.

Among the 65 studies testing pregabalin in Pain, Postoperative, this one is the 49th largest by enrollment, is one of 5 that started in 2020, is one of 5 in phase 1, and was the 46th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

7 of the 65 studies testing pregabalin in Pain, Postoperative are open now, in 5 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies testing pregabalin in Pain, Postoperative, or all of them as a file.
02

Study summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to determine a maximum tolerated dose of IV PGB and to evaluate the safety, tolerability, and PK of an admixture of IV PGB and a fixed dose of 1300 mg IV APAP in healthy adult volunteers.

Read the detailed description

This is a Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to determine a maximum tolerated dose (MTD) of IV PGB and to evaluate the safety, tolerability, and PK of an admixture of IV PGB and a fixed dose of 1300 mg IV APAP in healthy adult volunteers.

Up to 60 subjects will be enrolled into one (1) of six (6) sequential cohorts (n=10 per cohort [8 APAP + PGB and 2 placebo]).

The dose for the first cohort will be 1300 mg APAP and 100 mg PGB. For subsequent cohorts, the dose of APAP will remain constant at 1300 mg while the dose of PGB will be varied (will start with 100 mg TID and then based on tolerability will be either increased or decreased by 25 mg) based on Safety Monitoring Committee decision.

The placebo will be the saline solution.

03

Conditions studied

  • Postoperative Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 18 to 55 years, inclusive at time of Screening
  • (BMI) between 18.5 and 28.0 kg/m2 inclusive, with a minimum weight of 50 kg and a maximum of 100 kg
  • Healthy as determined by pre-study medical history, physical examination, vital signs, complete neurological examination, and 12-lead confirming normal sinus rhythm
  • Negative tests for surface antigen (HbsAg), virus antibody (anti-HCV), (HIV)-1 and HIV-2 antibody at Screening
  • Routine clinical laboratory tests should be within normal limits at Screening and Admission (Day -1) or abnormalities deemed not by the Investigator; for liver function tests, and ALT values should not be greater than 1.5 times the
  • Negative screen for drugs of abuse or exhibit detectable alcohol levels by breathalyzer at the time of Screening or Admission
  • Non-smokers or ex-smokers (must have ceased smoking ≥3 months prior Screening visit)

Female subjects:

  • Must be of non- by surgical sterilization or OR Must not be pregnant, breast feeding, or planning to become pregnant AND must be practicing both a highly effective method of from Screening until at least 90 days after the last dose of study drug.
  • Women of childbearing potential must have a negative pregnancy test result at Screening and upon admission to the Clinical Trial Unit.

Exclusion criteria

Exclusion Criteria:

  • Has a history or presence of respiratory, gastrointestinal, renal, hepatic, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders
  • Has a history of severe drug allergy, or severe or severe food allergy, including anaphylaxis or known allergy or sensitivity to any component of PGB or APAP
  • Has a history of alcoholism or drug abuse
  • Has acute gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea) at the time of Screening or Admission
  • Consumption of drugs with enzyme-inducing properties, within 3 weeks prior to the initial dose of study drug and throughout the treatment phase
  • Has used any prescription medicines, over the counter medicines, or herbal supplements, within 7 days of dosing
  • Has used any product or participated in any clinical trial within 30 days prior to Screening
  • Has donated or received any blood or blood products within the 3 months prior to Screening;
  • Not able to comply with the requirements of this study, including assessments, duration of admission of the study and expected follow up visits
  • Is unwilling or unable to give written
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    1300 mg Acetaminophen and 100 mg IV Pregabalin

    The dose for the first cohort will be 1300 mg APAP and 100 mg PGB. For subsequent cohorts, the dose of APAP will remain constant at 1300 mg while the dose of PGB will be varied (will start with 100 mg TID and then based on tolerability will be either increased or decreased by 25 mg based on Safety Monitoring Committee decision).

    Drug: Pregabalin 100mg · Drug: Acetaminophen 1300mg

  • No intervention
    Placebo

    Saline solution

  • Experimental
    1300 mg Acetaminophen and 100 mg +/- 25 IV Pregabalin

    Decisions to escalate or decrease the dose for Cohorts 2 through 6 will be dependent upon blinded review of emerging safety and tolerability data by the Safety Monitoring Committee (SMC). However, PK data is not part of the SMC review, but may be reviewed by a SMC designee at a later time.

    Drug: Pregabalin 100mg · Drug: Acetaminophen 1300mg

Interventions

  • Pregabalin is a structural derivative of the inhibitory neurotransmitter gamma aminobutyric acid with anticonvulsant, anxiolytic and sleep-modulating properties.

    Also known as: PGB

  • Acetaminophen is a non-salicylate antipyretic and non-opioid analgesic agent.

    Also known as: Ofirmev

06

What researchers measure

Primary outcomes

  1. Treatment Related Adverse Events

    The incidence and severity of treatment-emergent adverse events

    Time frame: 7 days

  2. Treatment related Drowsiness and Dizziness

    The incidence and severity of somnolence and dizziness

    Time frame: 7 days

Secondary outcomes

  1. Plasma PK endpoints for APAP and PGB, SAD Phase, Cmax

    Maximum observed concentration

    Time frame: 7 days

  2. Plasma PK endpoints for APAP and PGB, SAD Phase, Tmax

    Time to maximum observed drug concentration (Tmax)

    Time frame: 7 days

  3. Plasma PK endpoints for APAP and PGB, SAD Phase, t1/2

    Apparent elimination half-life

    Time frame: 7 days

  4. Plasma PK endpoints for APAP and PGB, SAD Phase, AUC0-last

    Area under the drug concentration-time curve from time zero to the last measurable concentration

    Time frame: 7 days

  5. Plasma PK endpoints for APAP and PGB, SAD Phase, AUC0-inf

    AUC from time zero to infinity

    Time frame: 7 days

  6. Plasma PK endpoints for APAP and PGB, SAD Phase, λz

    Apparent terminal elimination rate constant

    Time frame: 7 days

  7. Plasma PK endpoints for APAP and PGB, SAD Phase, CL

    Apparent clearance

    Time frame: 7 days

  8. Plasma PK endpoints for APAP and PGB, SAD Phase, Vz

    Apparent terminal volume of distribution

    Time frame: 7 days

  9. Plasma PK endpoints for APAP and PGB, multiple doses at steady state, AUCτ

    Area under the plasma concentration-time curve during a dosage interval

    Time frame: 7 days

  10. Plasma PK endpoints for APAP and PGB, multiple doses at steady state, Tmax,ss

    Time to Cmax at SS

    Time frame: 7 days

  11. Plasma PK endpoints for APAP and PGB, multiple doses at steady state, Cmax,ss

    Maximum concentration at SS

    Time frame: 7 days

  12. Plasma PK endpoints for APAP and PGB, multiple doses at steady state, Cmin,ss

    Minimum concentration at ss

    Time frame: 7 dyas

  13. Plasma PK endpoints for APAP and PGB, multiple doses at steady state, Cav,ss

    Average plasma concentration at SS

    Time frame: 7 days

  14. Plasma PK endpoints for APAP and PGB, multiple doses at steady state, Vz, ss

    Apparent volume of distribution at SS

    Time frame: 7 days

  15. Plasma PK endpoints for APAP and PGB, multiple doses at steady state, CLss

    Apparent total clearance at SS

    Time frame: 7 days

  16. Plasma PK endpoints for APAP and PGB, multiple doses at steady state, λz,ss

    Apparent first order terminal elimination rate constant at steady state

    Time frame: 7 days

  17. Plasma PK endpoints for APAP and PGB, multiple doses at steady state, R

    Accumulation index

    Time frame: 7 days

  18. Plasma PK endpoints for APAP and PGB, multiple doses at steady state, LF

    Linearity factor

    Time frame: 7 days

  19. Plasma PK endpoints for APAP and PGB, multiple doses at steady state

    Fluctuation ratio

    Time frame: 7 days

07

Study locations

1 site
  • Lotus Clinical Resarch,LLC
    Pasadena, California 91105, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Jun 2020, 5 months.

Of 83 phase 1 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 27. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2020
First posted
Feb 11, 2020
StartActual
Jan 14, 2020
Primary completionActual
Jun 15, 2020
CompletionActual
Jul 22, 2020
Last update
Aug 5, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04265456
Lead sponsor
Nevakar, Inc.
Responsible party
Sponsor
First posted
Feb 11, 2020
Start date
Jan 14, 2020
Primary completion
Jun 15, 2020
Completion
Jul 22, 2020
Last update
Aug 5, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pregabalin · Acetaminophen

Start the discussion